^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD52 inhibitor

    Related drugs:
    9d
    LemKids: A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT (clinicaltrials.gov)
    P3, N=16, Terminated, Genzyme, a Sanofi Company | Active, not recruiting --> Terminated; Enrolment formally closed earlier than planned due to recruitment challenges.
    Trial termination
    |
    Lemtrada (alemtuzumab)
    9d
    T-PLL: Observatory of Prolymphocytic Leukemia T (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, French Innovative Leukemia Organisation | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jun 2025 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    Campath (alemtuzumab)
    16d
    Asymptomatic T prolymphocytic leukemia: case report and literature review. (PubMed, Einstein (Sao Paulo))
    Standard therapies include alemtuzumab-based regimens and hematopoietic stem cell transplantation, although relapse rates remain high. This case underscores the need to recognize indolent presentations of T-cell prolymphocytic leukemia that may be managed conservatively. Further research is required to identify prognostic markers and optimize therapeutic strategies.
    Review • Journal
    |
    ATM (ATM serine/threonine kinase) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • STAT5B (Signal Transducer And Activator Of Transcription 5B) • TCL1A (TCL1 Family AKT Coactivator A)
    |
    ATM mutation
    |
    Campath (alemtuzumab)
    24d
    Islet Cell Transplant for Type 1 Diabetes (clinicaltrials.gov)
    P2, N=10, Active, not recruiting, City of Hope Medical Center | Trial completion date: Oct 2025 --> Sep 2026 | Trial primary completion date: Oct 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    Campath (alemtuzumab)
    2ms
    Effect of Alemtuzumab on Microglial Activation Positron Emission Tomography (PET) in Multiple Sclerosis (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, Brigham and Women's Hospital | N=10 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    Lemtrada (alemtuzumab)
    2ms
    Adding Azathioprine/Hydroxyurea Preconditioning to Alemtuzumab/TBI to Reduce Risk of Graft Failure in MSD HSCT in Adult SCD Patients (clinicaltrials.gov)
    P=N/A, N=20, Completed, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Recruiting --> Completed | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion • Trial completion date
    |
    Campath (alemtuzumab) • hydroxyurea
    2ms
    TRAVERSE: Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
    P1, N=120, Active, not recruiting, Allogene Therapeutics | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    cyclophosphamide • fludarabine IV • ALLO-316 • ALLO-647
    3ms
    A Rare Case of Renal Failure Caused by T-Cell Prolymphocytic Leukaemia Infiltration. (PubMed, Case Rep Hematol)
    He required haemodialysis, but was treated with pulsed methylprednisolone and alemtuzumab, with excellent renal recovery, although remission was not achieved. This case demonstrates that renal leukaemic infiltration must be considered in T-PLL patients with rapidly progressive renal failure, and that solid organ invasion should not contraindicate timely commencement of T-PLL-directed therapy with alemtuzumab.
    Journal
    |
    STAT5B (Signal Transducer And Activator Of Transcription 5B)
    |
    Campath (alemtuzumab)
    4ms
    Reduced Intensity Transplantation for Severe Sickle Cell Disease (clinicaltrials.gov)
    P2, N=40, Suspended, St. Jude Children's Research Hospital | Trial completion date: Aug 2027 --> Aug 2029
    Trial completion date
    |
    cyclophosphamide • Campath (alemtuzumab) • sirolimus • hydroxyurea • thiotepa • plerixafor
    4ms
    HLA-Identical Sibling Renal Transplant Tolerance (clinicaltrials.gov)
    P=N/A, N=88, Completed, Northwestern University | Active, not recruiting --> Completed
    Trial completion
    |
    Campath (alemtuzumab) • sirolimus
    4ms
    Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study (clinicaltrials.gov)
    P1/2, N=1, Recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Enrolling by invitation --> Recruiting
    Enrollment status
    |
    CD40LG (CD40 ligand)
    |
    Campath (alemtuzumab) • sirolimus • busulfan • Kepivance (palifermin)
    5ms
    Real-world safety and effectiveness of alemtuzumab as a conditioning regimen for hematopoietic stem cell transplantation. (PubMed, Int J Hematol)
    Engraftment was achieved in 55 of 58 patients (94.8%) at a median of 16 days after HSCT, and predefined success (engraftment without grade ≥ 3 graft-versus-host disease in hematologic malignancies or grade ≥ 2 in other diseases) was met in 51 of 58 patients (87.9%). These results support the manageable safety profile and effectiveness of alemtuzumab as preconditioning for HSCT in Japanese patients.
    Journal • Real-world evidence
    |
    CD52 (CD52 Molecule)
    |
    Campath (alemtuzumab)